Maturitas
Volume 55, Issue 1 , Pages 5-13 , 20 August 2006

Latin American position on the current status of hormone therapy during the menopausal transition and thereafter

Received 5 August 2005 ,Revised 10 March 2006 ,Accepted 29 March 2006.

References 

  1. Anonymous. Role of progestogen in hormone therapy of postmenopausal women: position statement of the North American Menopause Society. Menopause 2003; 10: 113–32.
  2. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199–210
  3. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461
  4. Anonymous. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004; 11: 589–600.
  5. Anonymous. Guidelines for hormone treatment of women in the menopausal transition and beyond . Position statement by the Executive Committee of the International Menopause Society. Climacteric. 2004;7:8–11
  6. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005;51:8–14
  7. Información y Formación para el Manejo Actual de la Mujer en su Climaterio. In: Siseles N ed. Buenos Aires: Ed. Ascune Hnos, 2005; 562-74 (In press at the time of the panel meeting).
  8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  9. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERSII). JAMA. 2002;288:49–57
  10. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary–artery atherosclerosis. N Engl J Med. 2000;343:522–529
  11. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary–artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535–545
  12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–333
  13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  14. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701–1712
  15. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med. 2006;166:357–365
  16. Westhoff C. Risk of pulmonary embolism/venous thrombosis. In:  Lobo RA,  Kelsey J,  Marcus R editor. Menopause biology and pathobiology. San Diego: Academic Press; 2000;p. 607–615
  17. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673–2684
  18. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2001;103:638–642
  19. Stein J, Ravnikar V. Postmenopausal compliance with hormone therapy. In:  Lobo RA editors. Treatment of the postmenopausal woman: basic and clinical aspects. Philadelphia: Lippincott Williams & Wilkins; 1999;p. 445–451
  20. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997;350:1047–1059
  21. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  22. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA. 2003;289:3243–3253
  23. Schneider LS. Estrogen and dementia. JAMA. 2004;291:3005–3007
  24. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA. 2004;291:2947–2958
  25. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003;289:2651–2662
  26. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA. 2003;289:2663–2672
  27. Kronenberg F. Hot flashes. In:  Lobo RA editors. Treatment of the postmenopausal woman: basic and clinical aspects. Philadelphia: Lippincott Williams & Wilkins; 1999;p. 157–177
  28. Bachmann GA, Ebert GA, Burd ID. Vulvovaginal complaints. In:  Lobo RA editors. Treatment of the postmenopausal woman: basic and clinical aspects. Philadelphia: Lippincott Williams & Wilkins; 1999;p. 195–201
  29. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:529–539
  30. Kanis JA. Diagnosis of osteoporosis. Osteoporos Int. 1997;7(Suppl. 3):S108–S116
  31. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668–2676
  32. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443–451
  33. Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol. 1981;20:413–416
  34. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059–2063
  35. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11:17–22
  36. Loprinzi CL, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc. 2002;77:1159–1163
  37. Basavilvazo MA, Bravo-Rodriguez LM, Carranza-Lira S, et al. Primer consenso nacional multidisciplinario sobre terapia de reemplazo hormonal. Rev del Clim. 2004;7:156–179
  38. Fernandes CE, Soares-Pereira A, Bonassi-Machado R, et al. Consenso da SOBRAC-Associação Brasileira de Climatério. Terapeutica hormonal na peri e na pós-menopausa. Cap. 7. Ed. Medcomm, 2004. São Paulo, Brasil.
  39. Campodónico I, Siseles N, Gutierrez P, et al. Consenso Latinoamericano sobre terapia hormonal postmenopausica (Memoria Mecanógrama). Salta, Argentina 14–15 de agosto de 2003. On file.
  40. Salkind NJ. Exploring research. 4th ed.. Upper Saddle River, NJ: Prentice Hall; 2000;p. 132–133

☆ Affiliation of Panel members are given in Appendix A.

PII: S0378-5122(06)00100-9

doi: 10.1016/j.maturitas.2006.03.009

Maturitas
Volume 55, Issue 1 , Pages 5-13 , 20 August 2006

Article Tools